top of page
< Back

Sofosbuvir: The Next Pre-Grant Opposition Target by I-MAK

After anti–influenza drug Tamiflu (Oseltamivir Phosphate) and antiretroviral drug Viread, Gilead Sciences is again back in news, this...

Sofosbuvir: The Next Pre-Grant Opposition Target by I-MAK

2013/12/10/sofosbuvir-the-next-pre-grant-opposition-target-by-i-mak/

bottom of page